# Specificity and Molecular Definition of Pathogenic Lymphocytes in Sjogren's Syndrome

> **NIH NIH R01** · OKLAHOMA MEDICAL RESEARCH FOUNDATION · 2020 · $540,620

## Abstract

PROJECT SUMMARY
Sjögren's syndrome (SS) is a rheumatic autoimmune disease selectively targeting salivary and lacrimal glands,
leading to painful dry mouth and eyes, oral infections, severe dental caries/tooth loss, fatigue, arthritis, neurologic
involvement, and malignant B cell lymphoma. There are no effective biologic therapies. The strongest genetic
risk factor is MHC class II DR3/DQ2. CD4+ T cells dominate salivary gland (SG) focal lymphocytic infiltrates,
but B cells are also present. CD4+ T cells drive germinal center formation and class-switched, somatically hyper-
mutated antibodies, all characteristic features of SS SG. Identification of the antigens and immunologic pathways
driving the aberrant immune responses in SS is the focus of our proposal. In previous work, we isolated paired
T cell receptor (TCR) α and β sequences of clonally expanded SG CD4+ T cells from DR3/DQ2+ patients and
showed that the degree of clonal expansion correlated with reduced salivary flow and increased SG fibrosis.
These are the first findings to link SG T cell infiltrates with low salivary flow and SG damage. Expanded clones
within and between patients showed TCR amino acid similarities at sites contacting antigenic peptide, providing
evidence that common antigen(s) drive SG CD4+ T cell proliferation. We used SG plasmablast-derived
monoclonal antibodies (mAbs) from the same patients to identify 15 new candidate autoantigens. We also
identified key transcripts overexpressed in SG CD4+ T cells that are characteristic of T follicular helper (Tfh)
cells or may promote Tfh differentiation (TNFSF8-encoded CD30L). This proposal will test three hypotheses: i)
previously unidentified antigens are targeted by SG CD4+ T cells and plasmablasts in SS, ii) autoreactivity to
novel antigens may explain oral and neurologic manifestations of SS, and iii) clonally expanded SG CD4+ T cells
express a unique transcriptional signature that promotes Tfh cell differentiation.
Aim 1. Determine whether shared TCRs expressed on clonally expanded SG CD4+ T cells are specific for
canonical and novel SS antigens bound by SG plasmablasts of the same subjects and are present in
peripheral blood (PB) of SS cases, with frequencies reflecting SG disease features and severity.
Aim 2. Identify the specificities of SS salivary gland plasmablast-derived mAbs and determine whether
they have functional consequences and/or cross react with canonical SS antigens.
Aim 3. Determine the transcriptional program of SG CD4+ T cells expressing shared, disease-associated
TCRs, validate their predicted phenotypes and their localization in SG tissue, and test the hypothesis
that CD30/CD30L signaling promotes human Tfh differentiation.
This high impact research will identify autoantigens and SG T cell properties that may explain oral and neurologic
SS pathology and that may be exploited to eliminate or regulate lymphocytes that drive chronic disease.

## Key facts

- **NIH application ID:** 9972861
- **Project number:** 5R01AR074310-03
- **Recipient organization:** OKLAHOMA MEDICAL RESEARCH FOUNDATION
- **Principal Investigator:** A Darise Farris
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $540,620
- **Award type:** 5
- **Project period:** 2018-09-10 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9972861

## Citation

> US National Institutes of Health, RePORTER application 9972861, Specificity and Molecular Definition of Pathogenic Lymphocytes in Sjogren's Syndrome (5R01AR074310-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9972861. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*